Oramed Pharmaceuticals Inc. (TLV:ORMP)
Israel · Delayed Price · Currency is ILS · Price in ILA 1,064.00
+1.00 (0.09%)
Jan 29, 2026, 5:24 PM IDT
Oramed Pharmaceuticals Revenue
Revenue (ttm)
$6.62M
Revenue Growth
n/a
P/S Ratio
64.66
Revenue / Employee
$1.66M
Employees
4
Market Cap
428.17M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.34M | -1.36M | -50.43% |
| Dec 31, 2022 | 2.70M | - | - |
| Aug 31, 2021 | 2.70M | -7.00K | -0.26% |
| Aug 31, 2020 | 2.71M | 7.00K | 0.26% |
| Aug 31, 2019 | 2.70M | 254.00K | 10.37% |
| Aug 31, 2018 | 2.45M | -7.00K | -0.29% |
| Aug 31, 2017 | 2.46M | 1.82M | 283.15% |
| Aug 31, 2016 | 641.00K | - | - |
| Aug 31, 2015 | - | - | - |
| Aug 31, 2014 | - | - | - |
| Aug 31, 2013 | - | - | - |
| Aug 31, 2012 | - | - | - |
| Aug 31, 2011 | - | - | - |
| Aug 31, 2010 | - | - | - |
| Aug 31, 2009 | - | - | - |
| Aug 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioLineRx | 42.17M |
| Evogene | 26.54M |
| XTL Biopharmaceuticals | 3.26M |
| Can-Fite BioPharma | 1.89M |
| Clal Biotechnology Industries | 91.00K |
| Geffen Residence & Renewal | 84.00K |
| BioLight Life Sciences | 21.00K |
Oramed Pharmaceuticals News
- 9 days ago - Hopwood Financial Services, Inc. Sells 200 Shares of Oramed Pharmaceuticals Inc (ORMP) - GuruFocus
- 16 days ago - Oramed To Transfer POD Technology To Lifeward; To Receive 49.9% Beneficial Ownership Interest - Nasdaq
- 16 days ago - Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company - GlobeNewsWire
- 16 days ago - Oramed and Lifeward Announce Strategic Transaction - PRNewsWire
- 22 days ago - Oramed receives $18 million payment from Scilex, approves $0.25 per share dividend - Seeking Alpha
- 22 days ago - Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments - Benzinga
- 22 days ago - Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments - PRNewsWire
- 5 weeks ago - Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback - Seeking Alpha